Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. - Wikidata - awgldk - TriplyDB

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.

http://www.wikidata.org/entity/Q35146269

about

Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells Role of multifaceted regulators in cancer glucose metabolism and their clinical significance Progress toward overcoming hypoxia-induced resistance to solid tumor therapy Role of hypoxia-inducible factors in breast cancer metastasis Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis Newly discovered angiogenesis inhibitors and their mechanisms of action Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1β): is it a rare exception?Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.Candidate biomarkers for cervical cancer treatment: Potential for clinical practice (Review).Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies Effects of hypoxia on human cancer cell line chemosensitivity.The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo.Hypoxia and the extracellular matrix: drivers of tumour metastasis Evaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases.Intravitreal Topotecan Inhibits Laser-induced Choroidal Neovascularization in a Rat Model.An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis.Molecular mechanisms mediating metastasis of hypoxic breast cancer cells.Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy.Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes.Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.Perspective: Opportunities in recalcitrant, rare and neglected tumors.Targeting the metabolic microenvironment of tumors.Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis.The potential role of HIF on tumour progression and dissemination.Metronomics: towards personalized chemotherapy?A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.Clinical overview of metronomic chemotherapy in breast cancer.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.The role of metabolic reprogramming in γ-herpesvirus-associated oncogenesis.Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiation of neuroblastoma cells.Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB.Epstein–Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas.

P2860

Q24613508-92C056C6-211A-4D2D-83F1-0971B7E51923 Q26765039-932D70DA-35A3-4132-85B3-2927F1D876C0 Q26796405-BA31CCE6-7C0D-46EF-92CA-4CCC468D6449 Q26860122-C30B6A65-24C9-4878-9AB3-6B93F472A3C0 Q26866144-D5B15979-E888-412F-ACD5-C89C358A4BBC Q26998498-73EBC639-4175-4F5A-BE96-C643CB8BB346 Q27027475-42D25B22-D5FE-4015-B17A-9CE3AB83F7AB Q33439523-0D949845-95B6-4C95-ABF5-17BF9D1A0876 Q33933054-E67FBF4C-75D7-447F-A0F3-0F3EC1829191 Q34023663-48BDCFF8-D6A2-46B4-9112-90BC10C3C82E Q34327123-E29D88D5-D907-4790-929A-5143E7AEA7D9 Q34799788-7FB13F1D-33F8-4862-A327-2C305888AFF9 Q34805346-B4E8BF7E-F7CD-4CC4-B846-DE7442536E53 Q34820282-3A0B82C2-0C83-4C71-97DC-6A73BBB4836B Q35448249-1FF56061-8EEE-4BB2-ABED-153A44EE3BA2 Q35884935-C0E1C9CD-9133-46DE-93E2-677523E1242B Q36163874-61D05CAC-15FE-409A-957F-941913847C39 Q36220497-7594C994-47E2-4090-AC76-A9FE0DD59A7E Q36220525-314B5B16-93F0-421A-BE3B-DFCC2423827B Q36254122-E65F3D40-AF5D-4085-BC09-DB6EF86BE2E0 Q36658324-A4F7B33C-A7FC-46BB-8E8A-EEE0B8AD9576 Q36737058-799732DE-8D48-411A-BC0E-E926CD4F9A0A Q36926098-BBA7199D-CB6D-4FB8-A838-BC9F07BBDAB6 Q37142438-FC4A078D-1B23-41D6-8C7D-94C4557D75E0 Q37197528-91A7752F-FDF6-402B-B04B-2F74790A17CA Q37229190-EDB3D478-F3E7-46DF-9A40-D426CAA535D1 Q37520563-5F55A44C-8759-404D-A8BF-4B054563FFCF Q38204343-17E9B00C-8891-488F-82B4-1CD2CEC35288 Q38218923-257211A4-70B8-4A29-88BE-F69D15C166AE Q38249998-EEFAB8E1-103B-4CD9-BB97-0C14B47E2457 Q38560651-BF84DC68-ECB8-4682-B5AC-76524AF56F0D Q38777221-7C3CAA67-054B-4491-994D-CABFB534B116 Q39077231-9AB3B940-ECE7-43E5-BAB6-D7AB3F0F8EBF Q39153126-90433B06-3F8F-4CE6-BDD3-372DDAF66969 Q39329214-830C1B85-A64E-4883-924C-1C70762C7074 Q40600188-8264A0AF-2E6A-4153-A48D-EAA713580D4D Q40854486-642EC414-1D2E-4849-9018-C549FA1624A4 Q52726721-7D9216C0-F36A-490F-9402-6753C6219752 Q54858561-A449FACD-BA7C-415A-A02D-9A92C0B0A5AD Q55272984-E9233795-E853-4B82-9DF5-8BE47568E976

P2860

Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors.

http://www.wikidata.org/entity/Q35146269

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Multihistology, target-driven ...... r-1α in advanced solid tumors.

@ast

Multihistology, target-driven ...... r-1α in advanced solid tumors.

@en

type

label

Multihistology, target-driven ...... r-1α in advanced solid tumors.

@ast

Multihistology, target-driven ...... r-1α in advanced solid tumors.

@en

prefLabel

Multihistology, target-driven ...... r-1α in advanced solid tumors.

@ast

Multihistology, target-driven ...... r-1α in advanced solid tumors.

@en

P1433

Q35146269-D676A63F-7D14-4BEB-9D01-CF7449BCFC5B

P1476

Q35146269-452C20D5-799F-4B61-9354-E2838BBA5EF7

P2093

Q35146269-1CE5FFAE-C1CA-462E-A03F-B17FA1ACB3D3

Q35146269-1E985257-C76E-46E0-B671-23CB992ADFAF

Q35146269-2CCEA79C-ECA9-4FC3-9AB2-ADF78F4A382D

Q35146269-34546D65-698B-49E5-9E4E-EC8414C44F80

Q35146269-42597523-4158-4B23-BF33-FB20818AA17D

Q35146269-6D30EBDD-AC14-4BA4-A469-4233F25DC05E

Q35146269-77D601F6-0012-4327-9448-26F2F1EA1F3D

Q35146269-85C9E9F6-A3FE-4E15-AF40-17A8AE7375CF

Q35146269-9082905C-77F6-4954-8B3D-AC0755D12EFC

Q35146269-AACF5051-B5E5-43FD-B66B-9E8775322377

P2860

Q35146269-00862DDB-7787-4138-97A8-BEE731D687FC

Q35146269-0865800D-C183-47DD-8BBF-7A1E5E217024

Q35146269-09F04603-E947-4993-857C-8FC47E79BCE1

Q35146269-0F40E07B-F3E6-4031-82B8-0C7F6835C384

Q35146269-27FE9C93-5FA5-4653-A414-4CEBE183DB4E

Q35146269-331063A2-7D36-4516-9089-9762E9670F17

Q35146269-4512CF6E-EEDF-4AD0-AEA6-B37C120953E2

Q35146269-655894E4-10F4-4F32-B704-75D8D6981919

Q35146269-765CA21C-A8C2-4A37-B838-5F481D68DBC0

Q35146269-89269606-75A4-476F-B444-51122AF084F0

P304

Q35146269-97CB0D86-3F6C-43A9-B364-22E7B8A4F039

P31

Q35146269-2C72F19F-D9A8-4083-898E-A43EC3231AEB

P356

Q35146269-2A3ED48C-4BC4-44E7-B668-8FF83D758265

P407

Q35146269-15BCB279-0168-424D-B7CF-1122A31442C1

P433

Q35146269-F7A615E5-96E5-42D3-8F3F-F48BF2A67E32

P478

Q35146269-6F789CF8-42FC-4DF0-9CED-B0C610C5094E

P577

Q35146269-A3536279-50B0-4003-9176-DBCD23EB61EA

P698

Q35146269-344F4A56-1827-4459-9957-D0BF10CE8910

P921

Q35146269-72B384BD-2BDD-4CC4-AF94-3C0D17057CD0

P932

Q35146269-9CC864FD-2294-4A9F-8E39-211C157B1B07

P356

1078-0432.CCR-11-0682

P1433

Clinical Cancer Research

P1476

Multihistology, target-driven ...... r-1α in advanced solid tumors.

@en

P2093

Agnes Strassberger

http://www.w3.org/2001/XMLSchema#string

Annamaria Rapisarda

http://www.w3.org/2001/XMLSchema#string

Anthony J Murgo

http://www.w3.org/2001/XMLSchema#string

Deborah Allen

http://www.w3.org/2001/XMLSchema#string

Giovanni Melillo

http://www.w3.org/2001/XMLSchema#string

Ismail Baris Turkbey

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Lamin Juwara

http://www.w3.org/2001/XMLSchema#string

Mark Raffeld

http://www.w3.org/2001/XMLSchema#string

Peter Choyke

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma

Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis

Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy

Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer

Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival

Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.

Development of HIF-1 inhibitors for cancer therapy

Targeting topoisomerase I to inhibit hypoxia inducible factor 1.

P304

5123-5131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-0682

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21673063

http://www.w3.org/2001/XMLSchema#string

P921

P932

3149769

http://www.w3.org/2001/XMLSchema#string